APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Varicella Attenuated Live Vaccine

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

Selected research

Market Structure

Global Varicella Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174045170321 December 2025186 pages

Choose your research edition.

Industry ResearchVaricella Attenuated Live Vaccine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Attenuated Live Vaccine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Varicella Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Attenuated Live Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.

The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.

Read the full market overview

This report provides an overview of the global Varicella Attenuated Live Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Attenuated Live Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Attenuated Live Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Attenuated Live Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Attenuated Live Vaccine Segment by Company

Merck

BCHT

Shanghai Institute

GSK

Keygen

Green Cross

Biken

Shanghai Rongsheng Biotech

Changchun Changsheng Life Sciences Limited

Varicella Attenuated Live Vaccine Segment by Type

Monovalent Vaccine

Combination Vaccine

Varicella Attenuated Live Vaccine Segment by Application

Kids Injection

Adults Injection

Varicella Attenuated Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Attenuated Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Attenuated Live Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Varicella Attenuated Live Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Varicella Attenuated Live Vaccine Industry Trends Table 2. Varicella Attenuated Live Vaccine Industry Drivers Table 3. Varicella Attenuated Live Vaccine Industry Opportunities and Challenges Table 4. Varicella Attenuated Live Vaccine Industry Restraints Table 5. Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Varicella Attenuated Live Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Varicella Attenuated Live Vaccine Sales by Manufacturers (k doses) & (2021-2026) Table 8. Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers Table 9. Global Varicella Attenuated Live Vaccine Average Sales Price (USD/dose) of Manufacturers (2021-2026) Table 10. Global Varicella Attenuated Live Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Varicella Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Varicella Attenuated Live Vaccine Manufacturers, Product Type & Application Table 13. Global Varicella Attenuated Live Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Attenuated Live Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monovalent Vaccine Table 17. Major Manufacturers of Combination Vaccine Table 18. Global Varicella Attenuated Live Vaccine Sales by Type 2021 VS 2025 VS 2032 (k doses) Table 19. Global Varicella Attenuated Live Vaccine Sales by Type (2021-2026) & (k doses) Table 20. Global Varicella Attenuated Live Vaccine Sales by Type (2027-2032) & (k doses) Table 21. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Varicella Attenuated Live Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k doses) Table 24. Global Varicella Attenuated Live Vaccine Revenue by Type (2021-2026) & (k doses) Table 25. Global Varicella Attenuated Live Vaccine Revenue by Type (2027-2032) & (k doses) Table 26. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Kids Injection Table 29. Major Manufacturers of Adults Injection Table 30. Global Varicella Attenuated Live Vaccine Sales by Application 2021 VS 2025 VS 2032 (k doses) Table 31. Global Varicella Attenuated Live Vaccine Sales by Application (2021-2026) & (k doses) Table 32. Global Varicella Attenuated Live Vaccine Sales by Application (2027-2032) & (k doses) Table 33. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Varicella Attenuated Live Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k doses) Table 36. Global Varicella Attenuated Live Vaccine Revenue by Application (2021-2026) & (k doses) Table 37. Global Varicella Attenuated Live Vaccine Revenue by Application (2027-2032) & (k doses) Table 38. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Varicella Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k doses) Table 41. Global Varicella Attenuated Live Vaccine Sales by Region (2021-2026) & (k doses) Table 42. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Varicella Attenuated Live Vaccine Sales Forecasted by Region (2027-2032) & (k doses) Table 44. Global Varicella Attenuated Live Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 46. North America Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 47. North America Varicella Attenuated Live Vaccine Sales by Country (2027-2032) & (k doses) Table 48. Europe Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 49. Europe Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 50. Europe Varicella Attenuated Live Vaccine Sales by Country (2027-2032) & (k doses) Table 51. Asia Pacific Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 52. Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 53. Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2027-2032) & (k doses) Table 54. South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k doses) Table 55. South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2021-2026) & (k doses) Table 56. South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2027-2032) & (k doses) Table 57. Global Varicella Attenuated Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Varicella Attenuated Live Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Varicella Attenuated Live Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2027-2032) Table 62. Merck Company Information Table 63. Merck Business Overview Table 64. Merck Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Merck Varicella Attenuated Live Vaccine Product Portfolio Table 66. Merck Recent Development Table 67. BCHT Company Information Table 68. BCHT Business Overview Table 69. BCHT Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. BCHT Varicella Attenuated Live Vaccine Product Portfolio Table 71. BCHT Recent Development Table 72. Shanghai Institute Company Information Table 73. Shanghai Institute Business Overview Table 74. Shanghai Institute Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio Table 76. Shanghai Institute Recent Development Table 77. GSK Company Information Table 78. GSK Business Overview Table 79. GSK Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. GSK Varicella Attenuated Live Vaccine Product Portfolio Table 81. GSK Recent Development Table 82. Keygen Company Information Table 83. Keygen Business Overview Table 84. Keygen Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Keygen Varicella Attenuated Live Vaccine Product Portfolio Table 86. Keygen Recent Development Table 87. Green Cross Company Information Table 88. Green Cross Business Overview Table 89. Green Cross Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Green Cross Varicella Attenuated Live Vaccine Product Portfolio Table 91. Green Cross Recent Development Table 92. Biken Company Information Table 93. Biken Business Overview Table 94. Biken Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Biken Varicella Attenuated Live Vaccine Product Portfolio Table 96. Biken Recent Development Table 97. Shanghai Rongsheng Biotech Company Information Table 98. Shanghai Rongsheng Biotech Business Overview Table 99. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio Table 101. Shanghai Rongsheng Biotech Recent Development Table 102. Changchun Changsheng Life Sciences Limited Company Information Table 103. Changchun Changsheng Life Sciences Limited Business Overview Table 104. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (k doses), Price (USD/dose), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio Table 106. Changchun Changsheng Life Sciences Limited Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Varicella Attenuated Live Vaccine Distributors List Table 110. Varicella Attenuated Live Vaccine Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Varicella Attenuated Live Vaccine Product Image Figure 2. Global Varicella Attenuated Live Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Attenuated Live Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Varicella Attenuated Live Vaccine Sales (2021-2032) & (k doses) Figure 5. Global Varicella Attenuated Live Vaccine Average Price (USD/dose) & (2021-2032) Figure 6. Global Top 5 and 10 Varicella Attenuated Live Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monovalent Vaccine Image Figure 9. Combination Vaccine Image Figure 10. Global Varicella Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k doses) Figure 11. Global Varicella Attenuated Live Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Varicella Attenuated Live Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k doses) Figure 14. Global Varicella Attenuated Live Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Kids Injection Image Figure 17. Adults Injection Image Figure 18. Global Varicella Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k doses) Figure 19. Global Varicella Attenuated Live Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Varicella Attenuated Live Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k doses) Figure 22. Global Varicella Attenuated Live Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 25. North America Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 27. Canada Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 28. Mexico Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 29. Europe Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 30. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 32. France Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 33. U.K. Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 34. Italy Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 35. Netherlands Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 36. Asia Pacific Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 37. Asia Pacific Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 39. Japan Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 40. South Korea Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 41. Southeast Asia Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 42. India Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 43. Australia Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 44. South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 45. South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 47. South Africa Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 48. Saudi Arabia Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 49. Turkey Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 50. Argentina Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 51. UAE Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 52. Egypt Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 53. Chile Varicella Attenuated Live Vaccine Sales and Growth Rate (2021-2032) & (k doses) Figure 54. Global Varicella Attenuated Live Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Varicella Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Varicella Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Varicella Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Varicella Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Varicella Attenuated Live Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Varicella Attenuated Live Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Monovalent Vaccine
  • Combination Vaccine
Applications
  • Kids Injection
  • Adults Injection
Companies covered
  • Merck
  • BCHT
  • Shanghai Institute
  • GSK
  • Keygen
  • Green Cross
  • Biken
  • Shanghai Rongsheng Biotech
  • Changchun Changsheng Life Sciences Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Varicella Attenuated Live Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Varicella Attenuated Live Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Varicella Attenuated Live Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Varicella Attenuated Live Vaccine Market Dynamics
  1. 2.1 Varicella Attenuated Live Vaccine Industry Trends
  2. 2.2 Varicella Attenuated Live Vaccine Industry Drivers
  3. 2.3 Varicella Attenuated Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Attenuated Live Vaccine Industry Restraints
3 Varicella Attenuated Live Vaccine Market by Manufacturers
  1. 3.1 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Varicella Attenuated Live Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Varicella Attenuated Live Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Varicella Attenuated Live Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Varicella Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Varicella Attenuated Live Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Varicella Attenuated Live Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Varicella Attenuated Live Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Varicella Attenuated Live Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Varicella Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3
4 Varicella Attenuated Live Vaccine Market by Type
  1. 4.1 Varicella Attenuated Live Vaccine Type Introduction
  2. 4.1.1 Monovalent Vaccine
  3. 4.1.2 Combination Vaccine
  4. 4.2 Global Varicella Attenuated Live Vaccine Sales by Type
  5. 4.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Attenuated Live Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Varicella Attenuated Live Vaccine Revenue by Type
  9. 4.3.1 Global Varicella Attenuated Live Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2021-2032)
5 Varicella Attenuated Live Vaccine Market by Application
  1. 5.1 Varicella Attenuated Live Vaccine Application Introduction
  2. 5.1.1 Kids Injection
  3. 5.1.2 Adults Injection
  4. 5.2 Global Varicella Attenuated Live Vaccine Sales by Application
  5. 5.2.1 Global Varicella Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Varicella Attenuated Live Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Varicella Attenuated Live Vaccine Revenue by Application
  9. 5.3.1 Global Varicella Attenuated Live Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2021-2032)
6 Global Varicella Attenuated Live Vaccine Sales by Region
  1. 6.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Attenuated Live Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Attenuated Live Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Varicella Attenuated Live Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Varicella Attenuated Live Vaccine Revenue by Region
  1. 7.1 Global Varicella Attenuated Live Vaccine Revenue by Region
  2. 7.1.1 Global Varicella Attenuated Live Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Varicella Attenuated Live Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Varicella Attenuated Live Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Varicella Attenuated Live Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Varicella Attenuated Live Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Varicella Attenuated Live Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Varicella Attenuated Live Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Varicella Attenuated Live Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 BCHT
  8. 8.2.1 BCHT Company Information
  9. 8.2.2 BCHT Business Overview
  10. 8.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
  12. 8.2.5 BCHT Recent Developments
  13. 8.3 Shanghai Institute
  14. 8.3.1 Shanghai Institute Company Information
  15. 8.3.2 Shanghai Institute Business Overview
  16. 8.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
  18. 8.3.5 Shanghai Institute Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Keygen
  26. 8.5.1 Keygen Company Information
  27. 8.5.2 Keygen Business Overview
  28. 8.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
  30. 8.5.5 Keygen Recent Developments
  31. 8.6 Green Cross
  32. 8.6.1 Green Cross Company Information
  33. 8.6.2 Green Cross Business Overview
  34. 8.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
  36. 8.6.5 Green Cross Recent Developments
  37. 8.7 Biken
  38. 8.7.1 Biken Company Information
  39. 8.7.2 Biken Business Overview
  40. 8.7.3 Biken Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
  42. 8.7.5 Biken Recent Developments
  43. 8.8 Shanghai Rongsheng Biotech
  44. 8.8.1 Shanghai Rongsheng Biotech Company Information
  45. 8.8.2 Shanghai Rongsheng Biotech Business Overview
  46. 8.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
  48. 8.8.5 Shanghai Rongsheng Biotech Recent Developments
  49. 8.9 Changchun Changsheng Life Sciences Limited
  50. 8.9.1 Changchun Changsheng Life Sciences Limited Company Information
  51. 8.9.2 Changchun Changsheng Life Sciences Limited Business Overview
  52. 8.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
  54. 8.9.5 Changchun Changsheng Life Sciences Limited Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Attenuated Live Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Attenuated Live Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Attenuated Live Vaccine Production Mode & Process
  6. 9.2 Varicella Attenuated Live Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Attenuated Live Vaccine Distributors
  9. 9.2.3 Varicella Attenuated Live Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst